Company news: Forest Labs

Share this article:
FDA approved Forest's Daliresp (roflumilast) for the treatment of severe chronic COPD in adults 18 and up. The daily pill is indicated for decreasing the frequency of flare-ups or worsening of symptoms including breathlessness, chronic cough and excessive phlegm associated with bronchitis. The first-in-class drug is not indicated for treatment of primary emphysema, another form of COPD.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters